# Frequently Asked Questions | Peptide Research Alliance > Answers to the most common questions about retatrutide, BPC-157, ipamorelin, PT-141, and NAD+ — plainly stated, cited, and honest about what the evidence does and doesn't show. The most common questions across all five compounds, answered plainly. ## What does retatrutide do? Retatrutide activates three hormone receptors simultaneously — the GLP-1 receptor, GIP receptor, and glucagon receptor — which together suppress appetite, improve glucose-dependent insulin secretion, and increase energy expenditure. In Phase 2 trials, this triple mechanism produced up to ~24% body-weight reduction at 48 weeks in adults with obesity and significant reductions in liver fat in participants with MASLD [4]. It is an investigational drug and not available outside clinical trials as an approved medicine. ## How does retatrutide work? Retatrutide is a single-molecule agonist at three receptors: GLP-1R, GIPR, and the glucagon receptor (GCGR). The GLP-1 and GIP arms suppress appetite and enhance insulin secretion; the glucagon arm adds energy expenditure and lipid mobilization. Cryo-EM structural data have resolved the molecule bound to all three receptor complexes and shown it is approximately 8.9× more potent at GIPR than native GIP [2]. The triple engagement is what distinguishes it from dual or single incretin approaches. ## How do I reconstitute retatrutide? This desk does not provide reconstitution instructions. Retatrutide is an investigational compound; providing preparation guidance would imply a context of use outside clinical oversight that we do not support. Any legitimate clinical-trial administration is handled by trial staff under approved protocols. For research-chemical material, no quality-verified reconstitution instructions can be responsibly provided by a literature-digest site. ## Is retatrutide FDA approved? No. As of mid-2026, retatrutide has not been approved by the FDA or any other regulatory agency. It is in Phase 3 clinical trials (the TRIUMPH program) conducted by Eli Lilly. It remains an investigational drug — legally administrable only under a clinical-trial protocol [1]. Material sold outside clinical trials as "retatrutide research chemical" is unregulated, of unverified identity, and not an approved medicine. ## What does BPC-157 do in the body? In animal models, BPC-157 promotes tissue repair primarily by stimulating the growth of new blood vessels through the VEGFR2 pathway [11]. It also modulates nitric-oxide signaling and has been shown to protect the gastric lining in rat models [12]. In the handful of human studies that exist — including a 2025 IV safety pilot in two adults [8] — no efficacy conclusions can be drawn. The honest answer is that what BPC-157 does in humans at any given use-case is not yet characterized by controlled evidence [9]. ## Is BPC-157 a growth hormone? No. BPC-157 is not a growth hormone, not a growth hormone secretagogue, and not a steroid. It is a 15-amino-acid peptide derived from a gastric protein, and its proposed mechanism is angiogenic and cytoprotective — primarily through VEGFR2 upregulation and nitric-oxide signaling [11]. It is not related to the GH axis. The confusion likely arises from claims about "tissue growth" in animal studies, but growth in the tissue-repair sense is mechanistically different from the GH/IGF-1 axis. ## Does BPC-157 work immediately? There is no controlled human evidence characterizing the timeline of BPC-157 effects in people. In animal models, some markers of healing improvement appear within days; in community reports, people describe first noticing changes in joint or gut symptoms within one to three weeks. These timelines are anecdotal and unverified. No pharmacokinetic study in humans exists beyond the 2025 two-person safety pilot [8]. The pharmacokinetic data in animals show a very short elimination half-life (under 30 minutes) [10], meaning individual doses do not persist — repeated administration in models was needed to sustain effects. ## Does BPC-157 damage the liver? No liver toxicity has been observed in the existing (very limited) human data: the 2025 IV safety pilot in two adults found no measurable changes in hepatic biomarkers [8]. In rodent studies, BPC-157 has generally been described as hepatoprotective — reducing liver damage in models of alcohol and drug-induced injury. The safety concern that should be honestly noted is not hepatotoxicity but rather the very thin human evidence base overall [9] and the unverified purity of commercially available products. ## What is ipamorelin? Ipamorelin is a synthetic pentapeptide that selectively activates the ghrelin receptor (GHS-R1a) on pituitary somatotrophs, triggering a pulse of growth hormone release. Its defining feature is that — unlike earlier growth-hormone-releasing peptides — it does this without meaningfully raising cortisol, ACTH, or prolactin [16]. It has never been approved as a drug anywhere, and its only Phase 2 clinical trial (for postoperative ileus) failed its primary endpoint [15]. It is sold as a research chemical and is prohibited in sport by WADA under category S2. ## What does ipamorelin do for you? Based on published human pharmacokinetic data, ipamorelin triggers a discrete growth hormone pulse (peaking approximately 40 minutes after IV dosing) in a dose-proportional manner [16]. GH pulses downstream influence IGF-1 production, tissue repair signaling, and metabolic functions. Community users frequently report improved sleep depth, faster recovery, and gradual body-composition changes — these are anecdotal, unverified self-reports, not clinical outcomes. The one Phase 2 efficacy trial did not demonstrate efficacy for its tested endpoint [15]. Claims about anti-aging, fat loss, or muscle gain in humans rest on mechanism and rodent data, not on controlled human trial evidence. ## What are the risks of ipamorelin? Documented risks include: a class-level cardiovascular signal (a related GHS-R1a agonist produced myocardial degeneration in 28-day rat studies) [14]; theoretical GH/IGF-1-mediated concern for tumor promotion in people with active or occult malignancy; possible appetite increase and adiposity effects from ghrelin-receptor activation; and unknown long-term human safety (the only controlled human data cover acute IV dosing in small samples) [15][16]. Practically: research-grade ipamorelin is of unverified purity; it is WADA-prohibited; and the FDA removed it from the pharmacy compounding eligible list in 2024. ## What is PT-141? PT-141 is the research-community name for bremelanotide, a synthetic cyclic heptapeptide approved by the FDA in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women [22]. It activates melanocortin receptors (primarily MC4R) in the brain, engaging the neural circuitry of sexual motivation rather than acting on peripheral blood flow. It is distinct from PDE-5 inhibitors in both mechanism and indication. ## What does the PT-141 peptide do? PT-141 activates MC4R and MC3R receptors concentrated in the hypothalamus and limbic system, engaging dopaminergic pathways involved in sexual desire and arousal. In a 2022 fMRI study in women with HSDD, MC4R agonism increased sexual desire for up to 24 hours and produced measurable changes in brain activation patterns in response to erotic stimuli [19]. Unlike blood-flow drugs, it works centrally on the *desire* component of sexual function — the motivation to want sex — rather than on the mechanical capacity to perform. It also activates pigmentation-related receptors, which can cause skin darkening with frequent use [22]. ## What is PT-141 used for? The only FDA-approved use is for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, at a 1.75 mg subcutaneous dose on an as-needed basis [22]. Phase 3 RECONNECT trials showed statistically significant improvement in sexual desire and reduction in desire-related distress over 24 weeks in this population [20]. All other uses — in men, in postmenopausal women, or for performance enhancement — are off-label and not supported by approved evidence. It is contraindicated in uncontrolled hypertension and known cardiovascular disease. ## What is NAD supplement used for? NAD+ supplements (typically taken as precursors NMN or NR, since oral NAD+ itself is poorly absorbed intact) are studied primarily for raising cellular NAD+ levels, which decline with age [26]. Research use cases include supporting energy metabolism, mitochondrial function, insulin sensitivity, and DNA repair signaling via sirtuin activation. In one human trial, oral NMN improved skeletal muscle insulin sensitivity in prediabetic postmenopausal women [25]. The 2025 *Nature Metabolism* review notes that translation to hard clinical endpoints in humans remains limited [23]. They are sold as dietary supplements, not drugs. ## What is the downside of taking NAD+? Oral NMN and NR are well-tolerated in controlled trials with no significant adverse events versus placebo [24][27]. The main practical concerns: (1) supplement-grade products vary widely in purity; (2) compounded injectable NAD+ has been subject to a Class I FDA recall for endotoxin contamination — an important distinction from oral supplements; (3) IV NAD+ given too rapidly causes chest discomfort, flushing, and nausea; (4) a theoretical concern exists that boosting NAD+ could support the metabolism of existing cancer cells, though this is not clinically characterized; (5) NMN's supplement regulatory status in the US is contested [23]. ## Is it safe to take NAD daily? In the controlled human trials reviewed here, daily oral NMN (for 60 days [24]) and daily oral NR (for 8 weeks [27]) were both well-tolerated with no significant safety signals compared to placebo. No long-term (years-long) controlled safety data exist. The trials studied specific dose ranges in specific populations; effects outside those contexts cannot be inferred. Compounded injectable NAD+ is a different product form with different safety considerations and should not be conflated with oral supplements. ## Does NAD cause weight gain? The controlled human trials of NMN and NR supplementation do not report weight gain as an effect [24][27]. The NMN insulin-sensitivity trial found no change in body composition [25]. There is no mechanistic or clinical evidence suggesting NAD+ supplementation causes weight gain. This is a commonly asked question that the published evidence does not support as a concern. --- An independent literature desk where every enthusiastic claim is immediately grounded in a citation and every gap in the evidence is stated plainly.